Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

437

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

December 20, 2023

Study Completion Date

March 1, 2024

Conditions
PreDiabetes
Interventions
DRUG

Life Style Intervention + Metformin

hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours

BEHAVIORAL

Life Style Intervention

hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week)

Trial Locations (1)

14080

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City

All Listed Sponsors
lead

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

OTHER

NCT05990205 - Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes | Biotech Hunter | Biotech Hunter